{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.5","upperLimit":"100.0","value":"100.0"},{"groupId":"OG001","lowerLimit":"19.4","upperLimit":"99.4","value":"75.0"},{"groupId":"OG002","lowerLimit":"0","upperLimit":"26.5","value":"0.0"},{"groupId":"OG003","lowerLimit":"0.0","upperLimit":"52.2","value":"0.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"5"}],"units":"Participants"}],"description":"ORR is defined as the percentage of patients with best overall response of complete response (CR) or partial response (PR) based on local assessment according to RECIST 1.1, RANO or Cheson hematological criteria.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients with a diagnosis of ALCL histologically or cytologically confirmed to be ALK-positive","id":"OG000","title":"Anaplastic Large Cell Lymphoma (ALCL)"},{"description":"Patients diagnosed with IMT with a confirmed translocation involving the ALK gene","id":"OG001","title":"Inflammatory Myofibroblastic Tumor (IMT)"},{"description":"Patients with GBM with a translocation involving the ALK gene","id":"OG002","title":"Glioblastoma (GBM)"},{"description":"Patients with any other ALK-positive tumor. Patients in this arm included adenocarcinoma (n= 2), sarcoma (1) and other (2).","id":"OG003","title":"Any Other ALK-positive Tumor"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Baseline, every 8 weeks until disease progression or end of treatment, whichever came first assessed up to approximately 84 weeks","title":"Overall Response Rate (ORR) Per Investigator Assessment","type":"SECONDARY","unitOfMeasure":"percentage of participants"}